Ovarian Cancer
17 Sept 2026 · 17 min read

On this page56 sections
Overview and Symptoms
Ovarian cancer is a prevalent malignancy affecting the female reproductive system. The ovaries are two small organs situated low in the abdomen, connected to the uterus (womb), which store eggs and produce reproductive hormones. While this cancer primarily develops in individuals over the age of 50 who have transitioned through menopause, it can also manifest in younger people.
Understanding the Symptoms
Early-stage ovarian cancer is notoriously difficult to recognize because its signs frequently mimic common, non-cancerous conditions like Irritable Bowel Syndrome (IBS) or Premenstrual Syndrome (PMS).
Direct Symptoms: The "BEAT" Acronym
Because there is no routine screening test for ovarian cancer, recognizing physical changes is vital. You can track the four primary symptoms using the word BEAT:
Bloating that is persistent and does not fluctuate or come and go.
Eating difficulties, including feeling full much faster than normal.
Abdominal or pelvic pain experienced on most days.
Toilet habit changes, such as needing to urinate more frequently or experiencing new constipation.
Supplementary Symptoms
Other physical changes associated with ovarian cancer include:
Pain or deep discomfort during sexual intercourse.
Chronic, unexplained back pain.
Persistent fatigue or lacking energy all the time.
Sudden, unintentional weight loss.
Important Note: Routine cervical screening (Smear/HPV tests) does not detect ovarian cancer; it screens exclusively for changes in the cervix.
When to Consult a GP
Schedule a Non-Urgent Appointment if You Experience:
Any of the primary or supplementary symptoms continuously for 3 weeks or more.
A significant family history of ovarian or breast cancer.
A first-time onset of Irritable Bowel Syndrome (IBS) symptoms after the age of 50.
Ongoing Monitoring
While these symptoms are far more likely to be caused by a benign condition, clinical evaluation is essential. If your GP conducts initial assessments but your symptoms persist, worsen, or fail to improve, contact your medical clinic to request a follow-up review.
Ovarian Cancer: Causes and Risk Factors
Ovarian cancer develops when genetic mutations cause abnormal cells within the ovaries to multiply rapidly and uncontrollably. These cells form a mass or tumor and can eventually spread to other parts of the body. While the exact trigger for this cellular mutation remains unknown, specific demographic, genetic, medical, and environmental factors can increase your overall risk.
Key Risk Factors
1. Advancing Age
The probability of developing ovarian cancer accelerates as you age, with the condition manifesting most frequently after menopause. Approximately 80% of individuals diagnosed are over the age of 50. However, certain rare subtypes of the disease can still occur in younger populations.
2. Genetic Alterations and Family History
Inherited Gene Mutations
A primary family history of the disease—such as a mother or sister having ovarian cancer—significantly heightens your risk. This correlation is often linked to inherited mutations in specific genes:
BRCA1 and BRCA2: These inherited mutations substantially increase the baseline risk for developing both ovarian and breast cancers.
Lynch Syndrome: This is an inherited genetic condition passed from parent to child. While predominantly known for raising colorectal and endometrial (womb) cancer risks, it also elevates the likelihood of developing ovarian cancer.
Note: Inherited genetic mutations account for roughly 10% of all diagnosed ovarian cancers. Having a relative with the disease does not guarantee that you carry a high-risk mutation.
3. Medical and Hormonal Factors
Endometriosis
Living with endometriosis—a condition where tissue similar to the lining of the womb grows outside the uterus—is associated with a slightly elevated statistical risk of developing ovarian cancer.
Hormone Replacement Therapy (HRT)
Medical data indicates that long-term use of Hormone Replacement Therapy (HRT) may slightly increase your risk of ovarian cancer. However, this marginal risk is considered very small and is thought to decline steadily once you cease treatment.
Lifestyle and Environmental Aggravators
Weight and Obesity
Carrying excess body weight or having obesity elevates your overall cancer risk. Managing your weight by optimizing sleep quality, maintaining consistent physical activity, and adopting a balanced diet can help reduce your vulnerability to weight-related medical conditions.
Tobacco Use
Smoking is directly linked to an increased risk of developing specific subtypes of ovarian cancer. Quitting smoking halts this localized cellular stress and reduces your risk of numerous other serious health conditions.
Workplace or Environmental Exposure
Asbestos: Inhalation or exposure to asbestos fibers—a material historically used in commercial insulation, flooring, and roofing—is a documented risk factor for ovarian cancer.
Talcum Powder: Some research suggests that applying talcum powder directly to the genital area might increase ovarian cancer risks. However, the scientific evidence remains inconclusive, and any potential risk is considered very minor.
When to Seek Advice
If you are concerned that your family history, genetic background, or lifestyle exposures place you at a higher risk for ovarian cancer, schedule a consultation with your GP to discuss clinical risk mapping or a referral to a genetic counselor.
Ovarian Cancer: Diagnosis, Staging, and Outlook
Primary Care Clinical Evaluation
If you exhibit persistent symptoms of ovarian cancer, your GP will perform an initial clinical workup. This medical evaluation typically involves:
Symptom & Family Review: Mapping your physical changes, general health metrics, and maternal history of ovarian or breast cancer.
Abdominal Examination: Gently palpating your abdomen to check for localized swelling, fluid retention, or abnormal masses.
Internal Pelvic Examination: Inserting gloved, lubricated fingers into the vagina to physically evaluate the cervix, uterus, and surrounding structures for structural changes or lumps.
Biochemical Screening: Drawing a blood sample to measure a specific protein biomarker called CA125.
Diagnostic Diagnostic Tests
1. The CA125 Tumour Marker Blood Test
CA125 is a protein biomarker shed into the bloodstream by certain ovarian cancer cells.
Limitations: An elevated CA125 level does not confirm a cancer diagnosis. Levels can spike due to benign conditions such as pregnancy, uterine fibroids, or endometriosis.
Early-Stage Variance: In the early stages of ovarian cancer, a CA125 blood panel can return a completely normal result. If your blood test is clear but your physical symptoms worsen or persist, you must be re-evaluated.
2. Diagnostic Ultrasound Imaging
If your CA125 assay is elevated, your GP will fast-track you for an ultrasound scan. This imaging uses high-frequency sound waves to map internal pelvic organs via two distinct methods:
Abdominal Ultrasound: A sonographer glides a handheld transducer probe over your lower abdomen to map the ovaries.
Transvaginal Ultrasound: A specialized, slender probe is inserted directly into the vagina to secure high-resolution images of the ovaries and uterus. While you will feel a sensation of physical pressure, the procedure is not typically painful.
Note: The resulting scans identify structural mutations, solid tumors, cysts, or localized fluid buildup (ascites).
3. Advanced Secondary Testing
If ultrasound imaging detects a pelvic abnormality, a specialist gynaecologist will coordinate advanced diagnostic tracking to evaluate tissue structure and cellular spread:
CT Scan: Utilizing cross-sectional X-rays to construct high-definition, 3D images of your abdominal and pelvic anatomy.
Laparoscopy (Keyhole Evaluation): Inserting a thin, lighted tube with a miniature camera through a small surgical incision in your abdomen to visually examine the organs.
Needle Biopsy: Passing a specialized needle through the abdominal wall under imaging guidance to extract a fluid or tissue sample for definitive laboratory testing.
Clinical Staging and Grading
The 4 Main Stages of Ovarian Cancer
If malignant cells are confirmed, your oncological team will assign a "stage" to describe the size of the tumor and the extent of its anatomical spread:
Stage 1: The malignancy is strictly confined within one or both ovaries and has not spread.
Stage 2: The cancer has extended past the ovaries into the localized pelvic cavity or the uterus.
Stage 3: The disease has breached the pelvic barrier, spreading into the wider abdominal cavity or invading the regional lymph nodes.
Stage 4: The cancer has metastasized to distant organs outside the abdominal cavity, such as the lungs or the liver.
Histological Grading
Your care team will also assign a "grade" to describe how the malignant cells look under a microscope. This predicts how aggressively the tumor is likely to behave:
Grade 1: Low-grade cells that look relatively normal and are likely to grow slowly.
Grade 3: High-grade cells that look highly abnormal and are likely to replicate and spread rapidly.
Prognosis and Clinical Outlook
The Importance of Early Detection: Diagnosing ovarian cancer in its earliest stages significantly increases the probability of achieving a successful, long-term cure.
The Challenge of Late Diagnosis: Because early symptoms are highly subtle, the disease is frequently caught only after it has metastasized into the abdomen, where a definitive cure may no longer be clinically viable.
Statistical Survival: Approximately 1 in 3 individuals diagnosed with ovarian cancer survives for at least 10 years post-diagnosis.
Recurrence Risk: Even after achieving complete surgical and chemical remission, ovarian cancer carries a high risk of returning within a few years. While recurrent disease is generally considered incurable, ongoing systemic chemotherapy can successfully suppress symptoms and hold the cancer in check for months or years.
Ovarian Cancer: Treatment Options
The primary clinical interventions for ovarian cancer are surgical removal and systemic cancer medications. Your multidisciplinary team (MDT)—consisting of oncologists, gynecological surgeons, nurses, and radiologists—will design a personalized treatment protocol.
The exact configuration of your therapy is dictated by:
The specific histological type and cellular grade of the cancer.
The stage of the tumor and whether it has metastasized.
Your baseline physical fitness and general health.
Note: For early-stage disease, the primary goal is a complete cure by eradicating all malignant tissue. For advanced or metastatic cancer, treatment shifts to a palliative focus, aiming to suppress symptoms, preserve quality of life, and control the progression of the disease for as long as possible.
Surgical Interventions
Surgery serves as the frontline treatment to debulk, remove, or eradicate as much of the tumor mass as possible.
Standard Surgical Procedures
Performed under general anaesthesia and typically requiring a hospital stay of several days, major debulking surgery usually involves the removal of:
Both ovaries and the fallopian tubes (bilateral salpingo-oophorectomy).
The uterus and cervix (total abdominal hysterectomy).
The omentum (a protective layer of fatty tissue inside the abdomen where ovarian cancer cells frequently seed).
Fertility-Sparing Variations
If the malignancy is strictly confined to a single ovary (Stage 1a) and you wish to preserve your childbearing potential, your surgeon may opt to remove only the affected ovary and its corresponding fallopian tube, leaving the healthy ovary and uterus intact.
Advanced Surgical Adjustments
In more widespread or complex cases, the surgeon may need to remove your appendix or sections of the bowel if malignant cells have invaded those tissues. If a bowel resection is performed, you may require a stoma (an opening created on the abdomen connected to an external collection bag). Full physical recovery from extensive debulking surgery can take several weeks.
Systemic Cancer Medications
1. Chemotherapy
Chemotherapy utilizes cytotoxic (cell-toxic) medications to disrupt the replication cycle of rapidly dividing cells and destroy them. It can be administered before surgery to shrink a large tumor (neoadjuvant) or after surgery to eliminate any microscopic residual disease (adjuvant).
2. Targeted Therapy
Targeted therapies are specialized medications engineered to identify and attack malignant cells without damaging healthy tissue. These drugs work by blocking specific genetic pathways or protein mutations (such as BRCA variations) that allow the tumor to grow. Your MDT will order genetic testing on your blood or a tumor sample to confirm if your specific cancer expresses the biomarkers needed to qualify for this therapy.
3. Hormone Therapy
Certain rare or low-grade ovarian tumors rely on systemic hormones to fuel their replication. Hormone therapy works by lowering the baseline production of these hormones in your body or physically blocking the hormones from attaching to the receptors on the cancer cells, effectively halting tumor growth.
Radiotherapy
Radiotherapy uses high-energy, precisely directed radiation beams to destroy cancer cells by damaging their DNA. It is not routinely used as a primary treatment for ovarian cancer, but your MDT may deploy it in two specific scenarios:
Adjuvant Care: Following early-stage surgery to sterilize the pelvic cavity and destroy any microscopic clusters of cancer cells left behind.
Palliative Care: To shrink localized secondary tumors and alleviate physical pain if the cancer has spread to distant bones or tissues and cannot be cured.
Side Effects: Common localized side effects include skin erythema (redness/soreness), severe fatigue, and localized hair loss within the precise path of the radiation beam. These typically resolve after your final session.
Clinical Trials
Clinical trials are tightly regulated scientific research studies evaluating next-generation therapies, novel drug combinations, or advanced surgical techniques. Participating in a trial can offer access to cutting-edge treatments that are not yet widely available to the public. Speak with your oncologist or care team to determine if there is an active clinical trial suitable for your specific diagnosis and stage.
Ovarian Cancer: Living With and Post-Treatment Care
Surgical Recovery Timeline
Surgical resection for ovarian cancer is a major clinical intervention. Complete tissue healing and physical recovery can take up to 3 months.
Weeks 1 to 2: Prioritize absolute pelvic and physical rest.
Weeks 3 and Beyond: Gradually reintroduce light, non-strenuous daily activities. Do not push your physical limits too quickly.
Work Clearance: Plan to take between 1 to 3 months off work, depending on the physical demands of your job.
Driving Restrictions: Avoid driving for approximately 1 month post-operation to allow abdominal muscles to heal and ensure rapid braking does not cause injury.
Exertion Limits: Strictly avoid strenuous lifting, heavy household chores, or high-intensity exercise for a minimum of 3 months. A physiotherapist can design a safe, phased recovery exercise plan.
Managing Treatment-Induced Early Menopause
If you were still having periods prior to surgery, the removal of both ovaries causes immediate surgical menopause. The sharp decline in estrogen production triggers immediate physical and systemic changes.
Symptom Control
Your oncologist or GP may prescribe Hormone Replacement Therapy (HRT) to control severe menopausal symptoms (like hot flushes or night sweats). HRT is generally recommended until you reach the average natural age of menopause (approximately 52 years), depending on your specific cancer type and medical history.
Bone Health and Osteoporosis Prevention
Estrogen plays a critical role in maintaining bone density. The sudden loss of this hormone increases your risk of developing osteoporosis (brittle bones vulnerable to fracture).
Eat a calcium-enriched diet and take daily Vitamin D supplements.
Undergo a baseline dual-energy X-ray absorptiometry (DEXA scan) to evaluate your bone mineral density.
Note: Repeat DEXA scans may be scheduled every few years, as osteoporosis develops progressively over time. If bone thinning is detected, your GP can prescribe bone-strengthening medications.
Post-Treatment Surveillance and Follow-Up
Ovarian cancer carries a high statistical risk of recurrence within the first few years after treatment ends. Continuous monitoring is vital.
Frequency: Follow-up appointments are typically scheduled every 3 months initially, gradually becoming less frequent over several years.
Monitoring: Expect regular CA125 blood panels and follow-up surveillance scans to screen for early signs of recurrence.
Action Step: Do not wait for your next scheduled appointment if you notice a return of any primary symptoms (such as persistent bloating, pelvic pain, or abdominal swelling). Contact your oncology care team or GP immediately.
Impact on Relationships, Sex, and Fertility
Intimacy and Sex Life
Avoid sexual intercourse for several weeks post-surgery to allow internal pelvic wounds to fully close and heal.
A temporary decline in libido or sexual desire is entirely normal. This can be driven by surgical menopause, chronic fatigue, physical stress, and emotional trauma. Speak openly with your partner and clear yourself of any pressure to resume intimacy before you feel ready.
Fertility Concerns
Surgical menopause permanently terminates childbearing capacity. If preserving your fertility is a primary concern, you must discuss experimental tissue or egg preservation options with your MDT prior to beginning surgery or chemotherapy.
Processing the loss of fertility can trigger deep grief. Seek emotional support from your specialist nurse, a counselor, or a dedicated peer network.
Pregnancy Warning: If you underwent chemotherapy but preserved your fertility, medically advise dictates avoiding pregnancy for at least two years. This buffer period ensures that if the cancer recurs rapidly, you can immediately undergo further oncological treatments without endangering a fetus.
Navigating a cancer diagnosis creates profound emotional, social, and financial challenges for patients and their families.
Community Support Networks
Most local communities host fully funded cancer support centers. These spaces offer free access to:
Professional psychological counseling and structured support groups.
Specialized manual lymphatic drainage therapies.
Cancer survivorship and tailored physical activity programs.
Complementary therapies.
Key Resources: For reliable clinical and lifestyle information, consult the Irish Cancer Society or thisisGO.
Reducing working hours or exiting the workforce during cancer treatments can destabilize your household finances. Contact a social worker or consult the Irish Cancer Society’s welfare and financial support guides early in your treatment pathway to determine your eligibility for illness benefits, medical cards, or specialized grants.
Advanced Palliative Care
If your ovarian cancer progresses to a stage where a clinical cure is no longer possible, medical focus transitions to advanced management.
Your MDT will integrate a specialized palliative care team into your care network, either in the hospital or within your home. Palliative specialists are experts in optimizing symptom control—such as aggressively managing chronic pain, bowel blockages, or nausea. Palliative medicine can be introduced months or years before end-of-life care, providing comprehensive physical, psychological, social, and spiritual support for both you and your family.
Disclaimer
The information provided here is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional or your GP for specific medical concerns, diagnoses, or health advice. Never disregard professional medical advice or delay seeking it because of information you have read here.
